Biopharma SHAKTI commits Rs. 10,000 crore to scale biologics manufacturing, translational research, and supply chains over five years, a strategic bet on biosimilars, advanced therapies, and domestic capacity. The fund aims to foster industry-academia incubators, incentives for advanced production, and a stronger export orientation. If executed, the scheme could reduce import dependence, lower therapy costs, and attract global investment into India’s next-generation drug industry. This measure requires clear timelines and state-level coordination.
Trending
- Sleep is essential for health, focus and well-being | Valley Life
- Man says Stephen Colbert joke ‘saved his life’
- Still looking for love in a barren wasteland of losers? Move to one of these ‘emotionally intelligent’ countries
- Social Security Payment for March 11, 2026: Schedule and eligibility explained — who gets paid this week?
- Who is Really Responsible for the Care Coordination in Healthcare?
- 10 Daily Habits that Often Waste 97 Percent of Our Time and Energy in Life
- Free boat rides, health camps mark Women’s Day fete
- Imagine Studio Releases New Trends Study Exploring the Future of Convenience, Loyalty, and Connected Well-Being
Wednesday, March 11
